SCHEMBL14368317

SCHEMBL14368317

CN(C)CCOc1ccc(NC=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.55
LTA4H P09960 2/20 0.51
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP2D6 P10635 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
POLB P06746 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14368316 0.92 KDM4E (0.57) HRH3KDM4EALDH1A1SMN1; SMN2CYP2D6
SCHEMBL20564261 0.84 EBP (0.53) HRH3LTA4HCYP2D6CYP1A2CYP2C9
SCHEMBL14418361 0.81 CHRNB2 (0.55) LTA4HKEAP1NFE2L2KDM4EALDH1A1
SCHEMBL9101297 0.81 MAPT (0.57) LTA4HKDM4EALDH1A1CYP2C9LMNA
SCHEMBL7533707 0.81 NPC1 (0.54) LTA4HKDM4EALDH1A1SMN1; SMN2CYP2D6
SCHEMBL11534933 0.79 APP (0.46) KDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL1640720 0.79 HRH3 (0.59) HRH3LTA4HKEAP1NFE2L2KDM4E
SCHEMBL12774576 0.78 HRH3 (0.50) HRH3LTA4HKEAP1NFE2L2KDM4E
SCHEMBL2089558 0.78 NPC1 (0.59) LTA4H
SCHEMBL18120853 0.77 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238734-A1 JNK INHIBITORS MAP3K7, MAPKAPK2, MAPK7 HRH3 4454/4885LTA4H 4630/4885KEAP1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.